|
1
|
American Cancer Society, : Cancer facts
and figures 2016. Journal 2016.
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), ; Darby S, McGale P, Correa C, Taylor
C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J,
et al: Effect of radiotherapy after breast-conserving surgery on
10-year recurrence and 15-year breast cancer death: Meta-analysis
of individual patient data for 10,801 women in 17 randomised
trials. Lancet. 378:1707–1716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wärnberg F, Garmo H, Emdin S, Hedberg V,
Adwall L, Sandelin K, Ringberg A, Karlsson P, Arnesson LG, Anderson
H, et al: Effect of radiotherapy after breast-conserving surgery
for ductal carcinoma in situ: 20 years follow-up in the randomized
SweDCIS Trial. J Clin Oncol. 32:3613–3618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang XZ, Chen Y, Chen WJ, Zhang X, Wu CC,
Zhang CY, Sun SS and Wu J: Effect of radiotherapy after
breast-conserving surgery in older patients with early breast
cancer and breast ductal carcinoma in situ: A meta-analysis.
Oncotarget. 8:28215–28225. 2017.PubMed/NCBI
|
|
6
|
Krug D, Baumann R, Budach W, Dunst J,
Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML,
et al: Current controversies in radiotherapy for breast cancer.
Radiat Oncol. 12:252017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ahmadloo N, Kadkhodaei B, Omidvari S,
Mosalaei A, Ansari M, Nasrollahi H, Hamedi SH and Mohammadianpanah
M: Lack of prophylactic effects of aloe vera gel on radiation
induced dermatitis in breast cancer patients. Asian Pac J Cancer
Prev. 18:1139–1143. 2017.PubMed/NCBI
|
|
8
|
Karlsson P: Postoperative radiotherapy
after DCIS: Useful for whom? Breast. 34 Suppl 1:S43–S46. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hirst DG and Robson T: Molecular biology:
The key to personalised treatment in radiation oncology? Br J
Radiol. 83:723–728. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsoutsou PG, Durham AD and Vozenin MC: A
need for biology-driven personalized radiotherapy in breast cancer.
Breast Cancer Res Treat. 167:603–604. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jang BS and Kim IA: A radiosensitivity
gene signature and PD-L1 status predict clinical outcome of
patients with invasive breast carcinoma in The Cancer Genome Atlas
(TCGA) dataset. Radiother Oncol. 124:403–410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lai Y, Chen Y, Lin Y and Ye L:
Down-regulation of LncRNA CCAT1 enhances radiosensitivity via
regulating miR-148b in breast cancer. Cell Biol Int. 42:227–236.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu G, Wang H, Zhang F, Tian Y, Tian Z,
Cai Z, Lim D and Feng Z: The effect of VPA on increasing
radiosensitivity in osteosarcoma cells and primary-culture cells
from chemical carcinogen-induced breast cancer in rats. Int J Mol
Sci. 18:E10272017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang X, Li Y, Wang D and Wei X: miR-22
suppresses tumorigenesis and improves radiosensitivity of breast
cancer cells by targeting Sirt1. Biol Res. 50:272017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou ZR, Yang ZZ, Wang SJ, Zhang L, Luo
JR, Feng Y, Yu XL, Chen XX and Guo XM: The Chk1 inhibitor MK-8776
increases the radiosensitivity of human triple-negative breast
cancer by inhibiting autophagy. Acta Pharmacol Sin. 38:513–523.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Salendo J, Spitzner M, Kramer F, Zhang X,
Jo P, Wolff HA, Kitz J, Kaulfuß S, Beißbarth T, Dobbelstein M, et
al: Identification of a microRNA expression signature for
chemoradiosensitivity of colorectal cancer cells, involving
miRNAs-320a, −224, −132 and let7g. Radiother Oncol. 108:451–457.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Spitzner M, Emons G, Kramer F, Gaedcke J,
Rave-Fränk M, Scharf JG, Burfeind P, Becker H, Beissbarth T,
Ghadimi BM, et al: A gene expression signature for
chemoradiosensitivity of colorectal cancer cells. Int J Radiat
Oncol Biol Phys. 78:1184–1192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hall JS, Iype R, Senra J, Taylor J,
Armenoult L, Oguejiofor K, Li Y, Stratford I, Stern PL, O'Connor
MJ, et al: Investigation of radiosensitivity gene signatures in
cancer cell lines. PLoS One. 9:e863292014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pramana J, Van den Brekel MW, van
Velthuysen ML, Wessels LF, Nuyten DS, Hofland I, Atsma D, Pimentel
N, Hoebers FJ, Rasch CR, et al: Gene expression profiling to
predict outcome after chemoradiation in head and neck cancer. Int J
Radiat Oncol Biol Phys. 69:1544–1552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Imadome K, Iwakawa M, Nakawatari M, Fujita
H, Kato S, Ohno T, Nakamura E, Ohkubo Y, Tamaki T, Kiyohara H, et
al: Subtypes of cervical adenosquamous carcinomas classified by
EpCAM expression related to radiosensitivity. Cancer Biol Ther.
10:1019–1026. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eschrich SA, Fulp WJ, Pawitan Y, Foekens
JA, Smid M, Martens JW, Echevarria M, Kamath V, Lee JH, Harris EE,
et al: Validation of a radiosensitivity molecular signature in
breast cancer. Clin Cancer Res. 18:5134–5143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten
DS, Nobel AB, van't Veer LJ and Perou CM: Concordance among
gene-expression-based predictors for breast cancer. N Engl J Med.
355:560–569. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Freidlin B, Jiang W and Simon R: The
cross-validated adaptive signature design. Clin Cancer Res.
16:691–698. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Freidlin B and Simon R: Adaptive signature
design: An adaptive clinical trial design for generating and
prospectively testing a gene expression signature for sensitive
patients. Clin Cancer Res. 11:7872–7878. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang Z, Zeng Q, Li Y, Zhang X, Ma J, Suto
MJ, Xu B and Yi N: Development of a radiosensitivity gene signature
for patients with soft tissue sarcoma. Oncotarget. 8:27428–27439.
2017.PubMed/NCBI
|
|
26
|
Zhu Y, Qiu P and Ji Y: TCGA-assembler:
Open-source software for retrieving and processing TCGA data. Nat
Methods. 11:599–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Molinaro AM, Simon R and Pfeiffer RM:
Prediction error estimation: A comparison of resampling methods.
Bioinformatics. 21:3301–3307. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Simon R, Radmacher MD, Dobbin K and
McShane LM: Pitfalls in the use of DNA microarray data for
diagnostic and prognostic classification. J Natl Cancer Inst.
95:14–18. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Grandi A, Santi A, Campagnoli S, Parri M,
De Camilli E, Song C, Jin B, Lacombe A, Castori-Eppenberger S,
Sarmientos P, et al: ERMP1, a novel potential oncogene involved in
UPR and oxidative stress defense, is highly expressed in human
cancer. Oncotarget. 7:63596–63610. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mulvihill MM, Benjamin DI, Ji X, Le Scolan
E, Louie SM, Shieh A, Green M, Narasimhalu T, Morris PJ, Luo K, et
al: Metabolic profiling reveals PAFAH1B3 as a critical driver of
breast cancer pathogenicity. Chem Biol. 21:831–840. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dolatshad H, Pellagatti A, Liberante FG,
Llorian M, Repapi E, Steeples V, Roy S, Scifo L, Armstrong RN, Shaw
J, et al: Cryptic splicing events in the iron transporter ABCB7 and
other key target genes in SF3B1-mutant myelodysplastic syndromes.
Leukemia. 30:2322–2331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang Z, Song Q, Zeng R, Li J, Li J, Lin
X, Chen X, Zhang J and Zheng Y: MicroRNA-218 inhibits EMT,
migration and invasion by targeting SFMBT1 and DCUN1D1 in cervical
cancer. Oncotarget. 7:45622–45636. 2016.PubMed/NCBI
|
|
33
|
Zhai JS, Song JG, Zhu CH, Wu K, Yao Y and
Li N: Expression of APPL1 is correlated with clinicopathologic
characteristics and poor prognosis in patients with gastric cancer.
Curr Oncol. 23:e95–e101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu Y, Zhang C, Zhao L, Du N, Hou N, Song
T and Huang C: APPL1 promotes the migration of gastric cancer cells
by regulating Akt2 phosphorylation. Int J Oncol. 51:1343–1351.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou J, Wu X, Li G, Gao X, Zhai M, Chen W,
Hu H and Tang Z: Prediction of radiosensitive patients with gastric
cancer by developing gene signature. Int J Oncol. 51:1067–1076.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tang Z, Zeng Q, Li Y, Zhang X, Suto MJ, Xu
B and Yi N: Predicting radiotherapy response for patients with soft
tissue sarcoma by developing a molecular signature. Oncol Rep.
38:2814–2824. 2017. View Article : Google Scholar : PubMed/NCBI
|
